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Since  its isolation  in  1957  by C.  Friend  (1),  the  Friend  virus complex  (FV) 1 has 
provided tumor virologists and immunologists with a  useful system for study of the 
pathogenetic mechanisms that regulate murine leukemia (2).  The biphasic nature of 
Friend disease, consisting of a rapid, frequently fatal, erythroblastic leukemia followed 
in survivors by a later lymphocytic neoplasm (3), led to the identification of two viral 
genomes in  FV  (4).  The early erythroleukemic phase of FV disease is effected by a 
defective virus genome, termed spleen focus-forming virus (SFFV)  because it can be 
assayed by the induction of splenic foci of proerythroblast proliferation 9 d postinfec- 
tion  (5).  The  later  lymphocytic phase  of FV  disease  is  effected  by a  nondefective 
helper  virus,  now  most commonly referred  to  as  Friend-murine  leukemia  virus  (F- 
MuLV)  (6).  Genetic studies of the susceptibility of mice to FV established that  the 
two phases of FV disease are controlled by at least two independent  loci (7-13). The 
Fv-1  locus, which  has n-alleles that  permit replication  of N-tropic but  restrict  repli- 
cation of B-tropic MuLV or b-alleles that  act conversely, affects both phases of FV 
disease when N-tropic or B-tropic MuLV strains are used as helper viruses  (12-14). 
The  Fv-2 locus,  at  which  sensitivity  alleles  are  dominant  to  resistance  alleles  (11), 
affects only focus formation by SFFV.  The mode of action of Fv-2 is not  yet clear; 
effects have been observed on SFFV replication (15) and on the proliferative status of 
erythroid target cells (16). 
Serologic studies of FV first demonstrated the utility of mouse typing serum in the 
analysis  of murine  leukemias  (17,  18).  Antibody  raised  in  C57BL/6  (B6)  mice  to 
syngeneic FV-induced  lymphocytic tumors, or in BALB/c mice to N-tropic FV, did 
not  cross-react  with  spontaneous  AKR  lymphomas  or  Gross  MuLV  lymphomas, 
whereas the sera did cross-react with lymphomas induced by the Rauscher or Moloney 
MuLV strains (17,  18), hence, the term Friend-Moloney-Rauscher (FMR) antigen. A 
similar cross-reactivity among the FMR  viruses was  found by transplantation  tests 
(19).  Proteins assigned to the gag- or env-gene regions have been implicated as FMR- 
bearing molecules (20, 21);  it is hoped that absorption of FMR typing antibody (18) 
with purified viral proteins will resolve this apparent discrepancy. Serologic identifi- 
cation of cell-surface antigens exclusively associated with SFFV has not yet succeeded, 
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though studies of cell-mediated cytotoxicity to tissue culture cells infected with SFFV 
or F-MuLV suggest such antigens exist  (22).  Furthermore,  studies  using heteroanti- 
body indicate  that  SFFV  shares  antigenic  determinants  with  env  gene  products  of 
recombinant mink cell focus-inducing (MCF)  FMR  MuLV strains  (23, 24). 
Our recent  serologic detection  of a  viral  tumor antigen  specified  by the  Abelson 
MuLV  defective  transforming  genome  (25),  and  the  similarities  of SFFV  to  the 
defective Abelson genome in terms of genome structure (6, 26), rapid oncogenie action 
(5, 27), and genetic control of susceptibility  (11, 28) prompted us to attempt a similar 
analysis  of SFFV.  In  so  doing,  we  have  been  cognizant  of the  fact  that  Abelson 
antigen  also  occurs  as  a  differentiation  antigen  on  bone  marrow  of uninfected 
susceptible  mice  (25);  indeed,  mice that  normally  express  this  determinant  do  not 
make  cytotoxic  anti-Abelson  antigen  antibodies  after  immunization  with  Abelson 
MuLV  tumor cells  (unpublished  observations).  If the putative  SFFV  antigen  were 
also a  differentiation  antigen  of susceptible  mice,  then  cytotoxic antibody to SFFV 
determinants  might be expected only in Fv-2  ~/" mice. 
Methods  and Materials 
Mice.  Mice  (BALB/cN, C57BL/6N,  or NFS/N)  were bred  in our colony. The partially 
congenic D2.RB strain  (87.5% DBA/2, but  carrying the Fv-U/r gene of C57BL/6)  (29) was 
obtained from Dr. F. Lilly and Dr. R. Steeves, Albert Einstein College of Medicine, N. Y. The 
congenic B6.S strain (B6-genetic background carrying the Fv-2  s gene of SIM) (9) was obtained 
from Dr. A. Axelrad, University of Toronto, Ontario. All other mice were purchased from The 
Jackson Laboratory, Bar Harbor, Maine. 
Cell Lines and  Viruses.  The ecotropic F-MuLV strain  201  (30) and dual-tropic Fr-MCF-1 
MuLV strain  (23) were obtained from Dr. D. Troxler,  National Cancer Institute,  Bethesda, 
Md.  Dr. Troxler also provided the SFFV-nonproducer cells;  SFFV-NRK C1  1, SFFV-NIH 
3T3, and SFFV-FRE (31). All other tissue culture cell lines and viruses were originally from the 
collection of Dr. J.  Hartley and Dr. W. P. Rowe, National Institute of Allergy and Infectious 
Diseases,  Bethesda,  Md., and have been maintained  in this laboratory as described in earlier 
publications (32, 33). Ecotropic MuLV were propagated on SC-1 cells and titered by the XC- 
plaque test  (34); dual-tropic MuLV were propagated in SC-1 cells and titered by fluorescent- 
antibody methods (35); xenotropic MuLV were propagated in mink cells (CCL64) and titered 
by fluorescent-antibody methods (35). Tissue culture cells were harvested for absorption tests 
according to published procedures (36). 
The animal passage strains of FV were obtained from Dr. F. Lilly, Albert Einstein College 
of Medicine, N. Y. NB-tropic and B-tropic FV strains were propagated and titered in BALB/ 
c mice, and N-tropic FV was propagated and titered  in DBA/2 mice as described  in earlier 
publications (5,  10, 14). Rauscher virus complex was provided by Dr. R. Steeves. 
Tumors and Target Cells.  The transplantable tumors RADA1, AKSL2, ASLI, Ec~G2, ERLD, 
EL4, Meth A, RL~I, MOPC-70A, and BALB RV1 were obtained from Dr. E.  Stockert and 
Dr. L. J. Old, Memorial Sloan-Kettering Cancer Center, N. Y.; the origin and maintenance of 
these tumors has been described (37). The B6 F-MuLV lymphoma FBL-3 and the B6 R-MuLV 
lymphoma RBL-5 were obtained from Dr. A. Fefef, University of Washington, Seattle, Wash. 
(19). The derivation and maintenance of the B6 Abelson MuLV lymphomas B6T1 and B6T3 
were  described  in  a  previous  publication  from  this  laboratory  (25).  The  transplantable  A- 
MuLV lymphoma, CT 1, was derived from the pooled lymphomatous tissue of the paravertebral 
region and enlarged lymph nodes of a 21/2-mo-old female BALB/cN mouse injected 50 d earlier 
with  103'° focus-forming units  (FFU) of cloned Abelson MuLV. The tumor is maintained by 
ascites  transfer of 107 cells/week in irradiated BALB/c mice. 
Tumors of the B6FR series were induced in B6 mice by intraperitoneal injection of 103.5 FFU 
of NB-tropic FV into neonates. The latent period for tumor appearance ranged from 4½ to 7½ 
too, and each tumor was diagnosed as splenic lymphoma. None of these tumors, established 
from lymphomatous spleens,  produced  SFFV,  though all  tumors produced high titers  of F- 1154  FRIEND ERYTHROLEUKEMIA ANTIGEN 
MuLV. Tumors are maintained by ascites transfer of 107 cells at weekly intervals in irradiated 
(800 rads) B6 mice. The B6 M-MuLV tumors were induced by intraperitoneal injection of 10  s 
plaque-forming units of M-MuLV into neonatal B6 mice. All tumors except B6FR~2 arose in 
female mice, and all were used in transplant generations 3-15. 
Friend  erythroleukemic spleen cells  were obtained by perfusion with  medium  199 of the 
massively enlarged spleens of mice infected 10-12 d earlier with  103.5 FFU of the appropriate 
FV strain.  Cells  obtained  in  this  manner  were  85-95%  viable  as judged  by  trypan  blue 
exclusion. The target Friend erythroleukemic spleen cells  (FEC) for the cytotoxic assay were 
obtained from the spleens of (C3H/HeJ  ×  B6)F1 mice infected 10-12 d earlier with  10  s's FFU 
of NB-tropic FV. 
Antisera.  BALB/c anti-FV serum was prepared by intraperitoneal injection into 10-wk-old 
female BALB/c mice of 102 FFU of N-tropic FV followed by injection of increasing doses of 
NB-tropic FV (17). B6 anti-FV serum was obtained after six intravenous injections of 10  s'~ FFU 
of NB-tropic  FV  into  female  B6  mice  at  bimonthly  intervals.  B6  anti-RBL-5  serum  was 
prepared by hyperimmunization of 10-wk-old B6 mice with living RBL-5 cells according to the 
immunization schedule detailed in our previous publication (25). Mice were bled from the tail 
vein in alternative weeks, and serum from each bleeding was pooled. Mice were reimmunized 
3-4 d after bleeding. 
Cytotoxic and Absorption Tests.  Direct cytotoxic tests were performed, as previously described 
(25,  37),  by incubation of equal  volumes (50 #1)  of 2.5  ×  10  s FEC, diluted  antiserum  and 
appropriately diluted rabbit serum (C source) at 37°C for 45 min. Viability counts were made 
in the presence of trypan blue. Preselected rabbit serum was used at a dilution of 1:5 or 1:7 in 
all tests with transplantable lymphoma cells (C control gave 10% lysis) and at a dilution of 1: 
15 in all tests with FEC (C control gave 13% lysis). 
Antibodies that  react with helper F-MuLV determinants  were removed from B6 anti-FV 
serum by absorption of 2 voi of antiserum, four- to sixfold more concentrated than that which 
gave 50% FEC lysis (generally a dilution of 1/20-1/40) with  1 vol of packed B6FR~2 cells at 
4°C for 30 min. Cells were removed by centrifugation at  1,000 g for 10 rain, and this FMR- 
preabsorbed antiserum was then used for typing of Friend Erythroleukemia antigen by a second 
absorption test.  B6FR~2-preabsorbed  antiserum  (50 pl)  was absorbed a  second time with a 
range of counted numbers of cells  for 30 rain at  4°C, and the residual cytotoxic activity for 
FEC  was  determined  in  direct  cytotoxic tests.  Cytotoxicity is  calculated  according to  the 
formula: (absorbed (percent lysis) -  C)/100 -  C. 
Results 
Serological  Reactivities  of Anti-FV Antisera.  The  Fv-2  resistance  gene  of B6  mice 
absolutely  inhibits  the  induction  of erythroleukemic  colonies by FV  (11),  but  only 
partially inhibits SFFV replication  (15). Thus, it follows that cytotoxic antibodies  to 
SFFV-specific antigens might be produced in B6 mice. After hyperimmunization with 
NB-tropic FV, B6 mice produced  antibodies  cytotoxic for (C3H/He  ×  B6)F1  FEC 
and  for  cells  of the  B6  F-MuLV  lymphoma  B6FR~2  (Fig.  1).  The  sensitivity  of 
B6FR~2  cells,  as well  as cells  from several  other  primary or transplanted  F-MuLV 
lymphomas, to lysis by B6 anti-FV serum was less than that of FEC. To distinguish 
a  quantitative difference in the amount of antigen expressed by these two target cells 
from a  qualitative  difference in the determinants  expressed,  absorption  experiments 
were carried out. 
Absorption of B6 anti-FV serum with B6FRc~2 cells completely removed cytotoxic 
activity  for B6FR~2  but  not  FEC  (Fig.  1).  The reactivity  of B6 anti-FV  serum  for 
B6FR¢~2 but not FEC, was also removed by absorption with SC- 1 tissue culture cells 
productively infected with NB-tropic F-MuLV (Fig.  1). Absorption with FEC, on the 
other hand,  removed all  cytotoxic activity for both  target  cells  (Fig.  1).  To exclude 
the possibility that  these results  were due solely to the greater sensitivity of FEC  to REX  RISSER  1155 
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Fro.  1.  Direct cytotoxic tests of B6 anti-FV serum on FEEl and B6FRd2 cells.  Antiserum diluted 
1/10 was absorbed with an equal volume of packed cells and then titered on the two target cells. 
FEC express an antigen(s) not expressed on B6FRd2 cells. Test cells:  FEC; []  [] B6FRd2. 
TABLE  I 
Serological Reactivities of Anti-FV Antisera 
Cytotoxicity 
No. mice  for FEC after  FE antigen  Antiserum  Serum titer*  immunized  B6FRd2 ab-  reactivity 
sorption.~ 
% 
BALB/c anti-FV  10  1/120  18  -- 
B6 anti-RBL-5  5  1/40  12  -- 
B6 anti-FV No. 1  6  1/160  40  + 
B6 anti-FV No. 2  18  1/200  55  + 
* The dilution of antiserum that resulted in 50% lysis of FEC in direct cytotoxic tests. 
:~ BALB/c anti-FV serum, diluted 1/20; B6 anti-RBL-5 serum, diluted 1/10; and B6 
anti-FV sera, diluted 1/20, were each absorbed with  1/2 vol of packed B6FRd2 
cells, and the residual cytotoxicity for FEC was then determined in direct cytotoxic 
tests. C control registered 13% lysis. 
lysis, a  second absorption of B6  anti-FV serum was carried out  with  B6FRd2  cells. 
Because  no  further  decrease  of cytotoxic activity for  FEC  was  observed  after  this 
second absorption of B6 anti-FV serum  (Fig.  1), it is likely that antibodies present in 
B6 anti-FV antiserum recognize determinants restricted to FEC, as well as determi- 
nants expressed on both cells. 
Earlier serologic studies of the FMR  antigen(s) indicated that the antigens detected 
on lymphoma and erythroleukemia cells were entirely cross-reactive (17-21).  Those 
studies differ from the present one in two important aspects: (a) anti-FV sera, which 
might be expected to recognize SFFV antigens, were prepared in Fv-2  s mice, primarily 
BALB/c  (17,  20);  and  (b)  when  antisera were  prepared  in  B6  mice, FMR  MuLV 
lymphomas, which  lack SFFV, were used  for immunization  (18,  19). Therefore, we 
have tested  two antisera, representative of earlier FMR-typing sera  (17,  18),  in our 
test  system.  The  data  in  Table  I  indicate that  antibody cytotoxic for  FEC  can  be 
completely removed from B6 anti-RBL-5 (a Rauscher MuLV  lymphoma) or BALB/ 1156 
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FIG.  2.  Quantitative  absorption tests of B6 anti-FV serum.  50/tl  antiserum,  diluted  1/30,  was 
absorbed with increasing numbers of the indicated cells, and the cytotoxicity remaining for FEC 
was then determined in direct cytotoxic tests. FEC and SFFV-NIH absorb all eytotoxic activity for 
FEC, whereas FMR cell lines show only partial absorption. 
c anti-FV antisera by absorption with B6FR~2; these results are thus consistent with 
previous studies (17-19). However, sera from two groups of FV-hyperimmunized B6 
mice contain antibody cytotoxic for FEC that cannot be removed by absorption with 
B6FRc~2. It should be noted that absorptions of B6 or BALB/c anti-FV antisera were 
performed at dilutions of 1/30 or 1/20, respectively, so that results from Table I might 
be compared to results from earlier studies (20, 21). However, later sera from 2 of the 
10 individual  BALB/c mice tested showed a  residual cytotoxic activity specific for 
FEC  when  sera were  absorbed  at  1/7.  This  low  titer antibody does  not  have  the 
alloantigen reactivity described below and has not been further analyzed. 
The results presented thus far indicate that two cytotoxic antibodies are present in 
B6 anti-FV serum;  one directed to determinants shared by FEC and B6FR~2, and 
the other directed to determinants expressed only on FEC. 
.Analysis of B6 Anti-FV Serum by Absorption with Primary  and Transplantable Mouse Tumors: 
Serological Definition of Friend Erythroleukemia (FE) Antigen.  The serological reactivities 
of B6  anti-FV  antiserum  were  analyzed  by  quantitative  absorption  tests  with  a 
number of tumors. Cells from a spontaneous AKR thymoma absorbed no cytotoxic 
activity, whereas absorption with FMR lymphoma cells or tissue culture cells produc- 
ing F-MuLV removed 40-50% of the cytotoxic activity for FEC (Fig. 2). To exclude 
the possibility that  the partial absorption shown by FMR  tumors reflected a  lower 
concentration of antigen  expressed on these tumors compared with  FEC, a  second 
quantitative absorption experiment was performed with a number of FMR lympho- 
mas using B6FRd2-preabsorbed B6 anti-FV antiserum. The results of this analysis, 
presented  in  Table  II  and  Fig.  3,  indicate  that  a  second  absorption  of B6FRc~2- 
preabsorbed serum  with  FMR  lymphomas  did  not  further reduce cytotoxicity for 
FEC. Erythroleukemias induced by SFFV, whether of FV or Rauscher virus origin, 
completely absorbed cytotoxic activity for FEC. This consistent pattern of reactivity 
suggests that a single antigenic system is detected by the cytotoxic activity of B6FRc~2- REX  RISSER 
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FE Antigen Phenotypes of FMR MuL V-lnduced Tumors 
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SFFV  FE antigen  Tumor  Strain of origin  Virus used for induction  produced*  eytotoxicity$ 
Test %~control  % 
Lymphomas 
CTI 
B6FR 1 
B6FRd2 
B6FR3 
Primary 
FBL-3 
Primary 
Primary 
B6Mo3 
RBL-5 
B6T 1 
B6T3 
Primary 
Primary 
Primary 
Primary 
Erythroleukemias 
Primary 
Primary 
Primary 
Primary 
Primary 
Primary 
Primary 
Primary 
Primary 
Primary 
Primary 
BALB/c  Abelson virus  ND  50/55 
B6  NB-tropic FV  0  35/39 
B6  NB-tropic FV  0  50/45 
B6  NB-tropic FV  0  47/45 
B6  NB-tropic FV  0  56/66 
B6  NB-tropic FV  0  42/43 
B6  M-MuLV  ND  49/39 
B6  M-MuLV  ND  52/55 
B6  M-MuLV  ND  41/45 
B6  Rauscher virus  0  61/55 
B6  Abelson virus  ND  54/55 
B6  Abelson virus  ND  65/55 
SWR  Cloned F-MuLV  0  35/43 
SWR  Cloned F-MuLV  0  39/66 
SWR  F-MuLV clone 201  0  49/66 
SWR  F-MuLV clone 20l  0  54/66 
A/J  B-tropic FV  -->103  4/90:[: 
BALB  B-tropic FV  ->103  10/90 
DBA/2  N-tropic FV  -> 10  z  10/90 
SWR  N-tropic FV  ->10  a  0/90 
A/J  NB-tropic FV  ->10  a  0/90 
BALB/c  NB-tropic FV  _>I0  a  0/90 
(BALB/c X B6)F~  NB-tropic FV  ->10  a  0/90 
(C3H ×  B6)F1  NB-tropic FV  ->10  a  0/90 
SWR  NB-tropic FV  -> 10  a  0/90 
BALB/c  Rauscher virus  ND  0/90 
(C3H  X B6)FI  Rauscher virus  ND  0/90 
* When tumors were harvested for serological analysis, a  10% wt/vol extract was prepared (11) and titered 
for SFFV (5). Units are in spleen foci/ml of extract. 
:[:The  expression  of FE antigen was  determined  by  quantitative  absorption  tests  of FE  typing serum 
(B6FRd2 preabsorbed B6 anti-FV antiserum) with counted numbers of cells of the indicated tumor. The 
cytotoxic activity remaining for FEC after absorption of FE typing serum (50/~1) with 2 ×  107 cells of the 
indicated tumor (test  %)  is to be compared with the cytotoxic activity of FE typing serum without a 
second  absorption as determined in the same test  (control  %). No FMR lymphoma removes cytotoxic 
antibody from FE typing serum. 
§ As it was anticipated that FV erythroleukemias would express  FMR antigen (17), unabsorbed B6 anti- 
from 1/20 to 1/40, was absorbed with 2  ×  10  erythroleukemia cells and the  FV serum (50 #1), diluted  7 
residual  cytotoxic activity for  FEC  determined.  FV  or  Rauscher  virus  erythroleukemias  remove all 
cytotoxic antibody for FEC from B6 anti-FV serum. 
preabsorbed  B6 anti-FV serum for FEC. We shall refer to the antigen detected by this 
test system as FE antigen to clearly distinguish  it from other FV-related determinants. 
We  have  examined  the  expression  of FE  antigen  on  a  number  of transplantable 
tumors of the mouse by quantitative absorption tests (Table III). None of these tumors 
remove cytotoxic activity from  FE  typing serum,  i.e.  B6FRd~2-preabsorbed  B6  anti- 
FV antiserum;  therefore they do not express this antigen.  From  the known  antigenic 
phenotypes of this panel of leukemia cells, we conclude that FE antigen is serologically 
unrelated to the previously defined cell surface alloantigens or MuLV-related  antigens 1158  FRIEND  ERYTHROLEUKEMIA  ANTIGEN 
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Fxo. 3.  Quantitative absorption tests of FE typing serum. B6 anti-]~v  * serum, diluted 1/30 and 
preabsorbed with  1/2  packed  vol  of B6FR¢~2 cells,  was  absorbed a  second  time with counted 
numbers of the indicated cells, and cytotoxicity remaining for FEC was then determined in direct 
cytotoxic tests.  FMR cell lines do not absorb cytotoxic antibodies from FE typing serum, whereas 
FEC and SFFV-NRK cells do. 
TABLE  III 
FE Antigen Phenotypes of Transplanted Tumors of the Mouse 
Tumor  Strain of origin  Tumor description  FE antigen 
cytotoxicity* 
Test %/control  % 
ASL 1  A/J  Spontaneous lymphoma  45/45 
RADAI  A/J  X-ray lymphoma  51/45 
Primary  AKR  Spontaneous lymphoma  33/39 
Primary  AKR  Spontaneous lymphoma  67/55 
AKSL2  AKR  Spontaneous lymphoma  52/55 
Meth A  BALB/e  Methylcholanthrene sarcoma  37/39 
MOPC-70A  BALB/c  Mineral oil plasmacytoma  35/46 
RL~I  BALB/c  X-ray lymphoma  37/45 
BALB RV1  BALB/c  Rad LV lymphoma  45/45 
EL4  B6  DMBA lymphoma  46/45 
F_,0"~2  B6  Gross MuLV lymphoma  33/45 
ERLD  B6  X-ray lymphoma  39/46 
Primary  SJL  Reticulum cell sarcoma  38/45 
Primary  SJL  Reticulum cell sarcoma  38/45 
Primary  SJL  Reticulum cell sarcoma  48/58 
* See footnote:~ of Table II for methods. None of this panel of transplanted or primary mouse 
tumors expresses  FE antigen. 
H-2, TL, Lyt series, Thy-l, PC. 1, Glx, G(RADA1), G(F_m,D), or G(AKSL2)  (37). In view of 
the syngeneic typing systemj i.e., B6 antiserum on (C3H  ×  B6)F1 cells, and lack of 
serological  cross-reactivity  between  FMR  typing  serum  and  naturally  occurring 
MuLV (17,  18), this result is not surprising. 
Expression of FE Antigen on MuL V-Infected Tissue Culture Cells.  The ability of MuLV 
strains to induce FE  antigen expression on tissue culture cells was determined by 
absorption  of FE  typing serum  with productively infected cells  (36).  Endogenous 
ecotropic or xenotropic MuLV strains do not induce the appearance of this determi- 
nant (Table IV). Antigens induced by the two dualtropic viruses MCF 247  and Fr 
MCF-1, which were isolated from a preleukemic AKR thymus (38) and a  F-MuLV 
lymphoma  (23),  respectively, do  not  react  with  FE  typing serum.  The  failure of 
endogenous ecotropic, xenotropic, or MCF-recombinant MuLVs (23,  38)  to absorb REX RISSI~R 
TABLE IV 
Induction of FE Antigen by Infection with MuL V ln Vitro 
MuLV strain  Virus titer*  FE antigen cyto- 
toxicity:~ 
Infectious U/ml  Test %~control  % 
Ecotropic MuLV 
Uninfected SC- 1  0  39/45 
AKR-L1  6.4  57/55 
WN 1802 N  5.8  61/55 
DBA/2 N-tropic  6.0  41/45 
B6 N-tropic  5.7  43/45 
M-MuLV  5.6  63/55 
F-MuLV  6.4  61/55 
Xenotropic MuLV 
Uninfected Mink  0  44/51 
NZB-IU  5.2  29/35 
BALB-IU  5.6  45/35 
DBA-IU  4.8  56/51 
Dualtropic MuLV 
MCF 247  5.3  33/39 
Fr MCF- 1  5.2  49/45 
SFFV nonproducer cells 
Uninfected NIH 3T3  ND  57/51 
SFFV-NIH  0  0/51 
Uninfected NRK  ND  51/51 
SFFV-NRK  0  6/51 
SFFV-FRE  0  0/51 
* At  the  time cells were harvested for absorption, supernatant  fluids were 
collected and  titered  for ecotropic MuLV  (34), xenotropic MuLV  (35), 
dualtropic MuLV (35), or SFFV (5). 
:~ See  footnote:l: of Table  II.  SFFV  nonproducer  cells but  not  ecotropic, 
xenotropic, or dualtropic MuLV-infected cells express FE antigen. 
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the  cytotoxic reactivity  of FE  typing  serum  establishes  the  viral  specificity  of this 
antigenic system. 
Recently,  mouse  and  rat  nonproducer  cell  lines  have  been  established  after  FV 
infection of cells  in  vitro  (31,  39).  Biological and biochemical  studies  have demon- 
strated  that  these lines carry only the SFFV genome and morphologically resemble 
the  parental  cell  lines  from  which  they  were  established  (31,  39).  Results  from 
quantitative  absorption experiments  indicate that the nonproducer cell SFFV-NRK 
expresses approximately the same quantity of FE antigen as FEC cells (Fig. 3). Similar 
results were observed with the other two SFFV nonproducer cell lines  (Table IV). It 
should  be  noted  that  SFFV-NIH  also  apparently  expresses  the  FMR  determinant 
detected by unabsorbed B6 anti-FV serum because absorption of B6 anti-FV antise- 
rum  with  SFFV-NIH  removed  all  cytotoxic  activity  for  FEC  (Fig.  2).  A  similar 
specification  of FMR  antigen(s)  by the  Abelson  defective  genome was observed  in 
studies of Abelson MuLV nonproducer cells (25). The serologic evidence presented so 
far defines a previously unrecognized viral cell-surface antigen of mouse leukemia, FE 
antigen.  Expression of FE antigen is limited to erythroleukemias induced by, or cell 
lines infected with SFFV. 
Expression of FE Antigen on Tissues of Uninfected Mice.  The appearance of FE antigen 
in hematopoietic tissues of uninfected mice was determined by quantitative absorption 1160  FRIEND  ERYTHROLEUKEMIA  ANTIGEN 
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Fro.  4.  Quantitative absorption tests for expression of FE antigen on tissues of uninfected mice. 50 
~| FE typing serum was absorbed with counted numbers of cells and residual cytotoxicity for FEC 
determined in  direct  cytotoxic tests. FE antigen in  uninfected  mice has  the characteristics of a 
differentiation antigen. C), ['eta] liver; O, bone marrow; [] peripheral blood; A, lymph node; --, 
FEC; ml spleen; &, thymus. 
tests with FE typing serum. Tissues of B6 and C57L mice uniformly typed negative 
for FE antigen expression. Bone marrow and spleen of BALB/c, DBA/2, SWR, and 
AKR mice were clearly positive; thymus, peripheral blood, and lymph node of these 
strains were negative (Fig. 4).  BALB/c and  SWR,  but not B6 mice, express FE on 
fetal liver;  the  absorptive capacity of this  tissue  is  about  threefold greater than of 
bone marrow (Fig. 4). Adult liver or kidney was negative in these three strains. Direct 
cytotoxic tests with FE typing serum did not  detect significant  lysis of BALB/c or 
SWR fetal liver, bone marrow, spleen, thymus, or lymph node cells.  The absorptive 
capacity of fetal  liver from  uninfected FE-positive mice  is  ----3% that  of FEC;  the 
absorptive capacity of bone marrow is ~1% that  of FEC;  and  positive spleen cells 
from uninfected mice have ~0.2% the absorptive capacity of FEC. Thus, results from 
quantitative absorption experiments and direct cytotoxic tests are consistent with the 
expression of FE by a minor cell population present in bone marrow, fetal liver, and 
spleen. Because cell-surface expression of FE in uninfected mice is a characteristic of 
only certain differentiated tissues, it is appropriate to also describe this determinant 
as a differentiation antigen. 
Genetic Control of FE Antigen in  Uninfected Mice: Concordance of Antigen Expression with 
Inheritance of the Fv-2  s  Virus Sensitivity Allele.  We have typed bone marrow of several 
inbred strains for expression of FE by quantitative absorption tests. Only mice of the 
C57-C58 family were negative; all other inbred strains express FE antigen on bone 
marrow (Table V). This strain distribution profile is reminiscent of that observed for 
the  Fv-2  locus  (40). Therefore, we have tested BALB/c  ×  B6 recombinant  inbred 
strains, i.e.,  the seven strains generated by Bailey (41) by inbreeding BALB/c  ×  B6 
Fz mice, for expression of FE antigen. Again, expression of FE antigen was concordant 
with inheritance of the Fv-2  s allele (Table V)  (42). 
Four congenic strains that have substituted Fv-2 regions were tested for expression 
of FE antigen. The strains B10.C(47N) and B6.C-H-7  b were made by substitution of 
the BALB/c H-7 histocompatibility locus onto the respective C57BL/10 or B6 genetic 
backgrounds (43, 44). Because H-7 is tightly linked to Fv-2, these strains also carry the REX  RISSER  1161 
TABLE g 
Expression of FE Antigen on Bone Marrow from Inbred,  Recombinant  Inbred, and 
Congenic Mouse Strains 
Fv-2 s strains  Fv-2  ~ strains 
Inbred Strains 
A/J  0/35*  DBA/2 
AKR  0/56  NZB 
BALB/e  0/52  NFS 
CBA/J  8/66  SJL 
CE/J  0/35  SWR 
C3H/HeJ  1/35  129 
Recombinant Inbred Strains 
CXB D  8/52 
CXB E  5/52 
CXB G  7/52 
CXB J  7/45 
CXB K  8/52 
Congenic Strains 
B10.C(47N)  0/58 
B6.C-H-7b:[:  0/58 
B6.S  1/42 
0/52  C57BL/6(B6)  56/55 
0/45  C57BL/10  51/48 
1/35  C57BR/cdJ  30/45 
0/35  C57L  39/45 
0/52  c58/j  38/45 
7/45 
CXB H  49/52 
CXB I  38/45 
D2.RB  48/58 
* The numbers indicate the (test %/control %) cytotoxicity  for FE antigen as described 
in footnote:~  of Table II. All Fv-2 s strains express FE antigen, but no Fv-2 r strain 
does. 
:~ Typed in this laboratory. 
Fv-2 allele of BALB/c  (8,  D.  Bailey and  W.  Rowe,  personal  communication).  The 
congenic strain B6.S was derived by substitution of the Fv-2  ~ allele of B6 with the Fv- 
2 s  allele of SIM (9).  The partially congenic D2.RB strain was constructed  by three 
backcrosses to DBA from B6 with selection for Fv-U heterozygosity at each'generation 
(29). Mice then were interbred, and Fv-2  "/r homozygotes used to establish the D2.RB 
line,  which  is  in  its  14th  generation  of inbreeding;  D2.RB  is  ~87.5%  DBA genetic 
background (R. Steeves, personal communication). Data from quantitative absorption 
tests  of FE-antigen  expression  on  bone  marrow  of parental  and  congenic  strains, 
presented in Fig. 5, indicate that "substitution of the Fv-2 region of B6 or C57BL/10 
with that of BALB/c or SIM results in FE antigen expression; conversely, substitution 
of  the  Fv-2  region  of  DBA/2  with  that  of  B6  results  in  the  loss  of  expression. 
Participation of the H-7-histocompatibility antigens in this serological typing system 
is excluded because B6 and DBA mice do not differ at this locus (40). 
Discussion 
The FE antigenic system identifies the second differentiation alloantigen that has 
been  specifically  associated  with  the  defective  transforming  genome  of a  rapidly 
oncogenic MuLV.  Absorption tests with FE typing serum establish that  this immu- 
nogenetic system does not cross-react with previously described cell-surface antigens 
of mouse leukemia (37), induced by viral or cellular genes. The consistent appearance 
of FE in FV and Rauscher virus erythroleukemias and its absence from lymphomas 
of diverse origin support the designation of this determinant as an antigen of virally 
induced erythroleukemic differentiation. However, FE is not limited to erythroleuke- 
mias,  but  also  appears on  fibroblastoid  cells  carrying  the  SFFV  genome,  and  on 1162  FRIEND  ERYTHROLEUKEMIA  ANTIGEN 
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FIG.  5.  Quantitative absorption tests of FE typing serum with bone marrow from parental and Fv- 
2 congenic mouse strains. Counted numbers of bone marrow cells from the indicated strain were 
used to absorb 50 #1  FE typing serum, and residual cytotoxicity for FEC was then determined. 
Expression of FE antigen is a trait that cosegregates with the Fv-2  s virus sensitivity allele. Parental 
strains: r-I, C57BL/10;  O, B6;  A, DBA/2; C), BALB/c. Congenic strains: O, D2.RB; I-'1, B6.S; A, 
B6.C-H-7; O, BI0.C(47N). 
uninfected fetal liver, bone marrow, and spleen cells of Fv-2  s  mice. 
Absorption experiments with B6 anti-FV antiserum indicated that SFFV nonpro- 
ducer cells and  FMR  lymphoma cells share antigenic determinants.  An  analogous 
expression of FMR determinant(s) on Abelson virus nonproducer cells was noted in 
a previous study (25). As both defective virus genomes share some gag but not env gene 
products with their respective helper viruses, proteins encoded by the gag region are 
logical  candidates  for  FMR-bearing  molecules.  Previous work  suggested  that  this 
might be the case (20), however, more recent studies indicate env gene-products bear 
the  FMR  determinants  (21).  The  recent  observation  that  FMR  MuLV  are  more 
efficient  for  oncogenesis  by,  but  not  replication  of,  FMR-derived  defective virus 
genomes (45, 46; Dr. D. Troxler, personal communication) may suggest the interaction 
of related molecular determinants in leukemogenesis by this family of MuLV. Further 
serological and biochemical analysis of the FMR antigenic system, which identifies 
such determinants, may clarify this point. 
A  conclusion consistent  with  the appearance of FE  antigen  on non-transformed 
SFFV-infected  fibroblasts  is  that  cell-surface expression  of FE  is  programmed  by 
SFFV rather than erythroleukemic differentiation per se. The simplest explanation 
for such a viral program is that SFFV encodes FE antigen, a proposition that can be 
substantiated  only by biochemical identification of FE antigen.  Accumulating evi- 
dence  points  to  the  recombinational  origin  of SFFV  (24,  31,  39,  47),  and  other 
pathogenic MuLVs (38, 48, 49); thus, it is possible that SFFV arose by recombination 
between exogenous helper MuLV and  the cellular sequences encoding FE antigen. 
The  initial  appearance  of erythroleukemia-inducing activity  in  FV  after  passage 
through Swiss  mice (1), and in Rauscher virus after passage through BALB/c mice 
(50) is consistent with this hypothesis, because these two strains express FE antigen on 
uninfected hematopoietic tissue.  Results from molecular hybridization experiments 
indicate  that  SFFV-specific  nucleotide sequences can  be  detected  in  the  DNA  of 
uninfected mice; the appearance of these sequences in RNA shows a  differentiative REX RISSER  1163 
program  similar  to  that  described  for  FE  antigen  (Bernstein  and  Mak,  personal 
communication). It will be of interest to determine if the presence of such sequences 
in DNA or in RNA also shows genetic polymorphism. 
The alternative explanation that FE antigen is universally encoded in mice and 
rats and induced by SFFV functions, has a precedent in the TL antigenic system (51). 
TL antigen is a  thymocyte differentiation antigen in some strains of mice; in other 
strains,  which  do  not  normally  express  this  determinant,  TL  is  an  antigen  of 
preleukemic  and  leukemic  differentiation  (37,  51).  Only  TL-  mice  produce  TL 
antibody (37). In these regards, our observations on FE antigen parallel those on TL; 
however, no TL-inducing virus has yet been identified (37). 
The detection of FE antigen on a  minor cell population present in bone marrow, 
fetal liver, and spleen suggests that this determinant is an alloantigen of primitive 
hematopoietic differentiation. Preliminary experiments indicate that FE antigen is 
expressed on some hematopoietic colony-forming cells.  Because the active organs of 
erythropoiesis in the mouse are  fetal liver, bone marrow, and spleen, and because 
expression of FE antigen shows a similar pattern of expression, it may also be expressed 
on primitive cells committed to erythroid differentiation. It is worth noting that the 
immunogenetic system that regulates transplantation of spleen colony-forming ceils 
has also been implicated in resistance to FV erythroleukemia (52).  Perhaps the FE 
antigen with its dual appearance on SFFV cells and hematopoietic colony-forming 
cells, is an antigen recognized by this unusual immunogenetic system. 
Relevant to a  discussion of the normal differentiative functions of the FE antigen 
is the observation that FE antigen appears to be controlled by the Fv-2 locus. Though 
all  tests  demonstrated  cosegregation  of FE  with  Fv-2  s,  it  is  possible  that  FE  is 
controlled by a  gene in the Fv-2 region and not the susceptibility factor itself. Only 
more extensive genetic tests can clarify this point. The studies of Steeves et al. on the 
partially congenic D2.RB strain indicated that Fv-2  r has an inhibitory effect on SFFV 
replication but  not on  virus  infection (15).  Blank and  Lilly went on  to make the 
surprising observation that  the fully congenic  DBA-Fv-2  ~/" genotype is apparently 
lethal in utero because no Fv-2  ~/" mice were recovered when 14th generation DBA-Fv- 
2 s/" heterozygotes were intermated (53). The results of Axelrad et al., using B6 and 
B6.S strains, indicated that the primary effect of Fv-2 may be physiologic control of 
erythroid progenitor cell proliferation(16). If Fv-2  s determines the presence of a cell- 
surface antigen as our results indicate, and if such an antigen were a necessary signal 
for hematopoietic proliferation and differentiation in certain genetic backgrounds, 
then genetic removal of such a  determinant would half normal development. The 
unconventional inheritance patterns of the Gix antigen, an MuLV-related cell-surface 
structure,  could  be  similarly  interpreted  to  result  from  unfavorable  cell-surface 
interactions in normal development (54, 55). These two immunogenetic systems--Fv- 
2-controlled  FE antigen and  Gv-l-controlled  Gxx antigen--provide  evidence for a 
physiologic role of MuLV-related cell-surface antigens in normal development. 
A possible role for FE antigen is that of a cell-surface signal or receptor involved in 
proliferation  and  differentiation of the  erythroid  pathway,  perhaps  as  a  critical 
determinant of the hematopoietic inductive microenvironment (56).  The control of 
FE  antigen by SFFV  or by Fv-2  s  would thus reflect the fact that  both  viral  and 
cellular genes control cell proliferation through a common mechanism. The observa- 
tions ofAxelrad et al. (16) that erythroid burst-forming cells are more rapidly dividing 1164  FRIEND ERYTHROLEUKEMIA ANTIGEN 
in B6.S than in B6 mice (and thus more likely to be transformed), might lend support 
to this idea.  Alternatively, FE antigen might  function as a  tissue-specific self-recog- 
nition structure. In such a ease, the failure of SFFV-infected cells to differentiate into 
erythroblastic colonies in  Fv-2  r/r mice may result  from a  failure of self-recognition. 
The C57-C58 family of mice have apparently evolved alternative structures to effect 
the same result. 
The FE antigenic system appears quite similar to that described for Abelson antigen 
(25).  Each antigen is specified by a defective transforming genome of MuLV, though 
the  tissue  specificity of these  two  viruses  is  quite  different.  Each  antigen  is  also  a 
normal differentiation alloantigen of bone marrow, fetal liver, and spleen in uninfected 
mice of the strain from which the defective virus was first isolated.  Each antigen is 
apparently controlled by a  dominant sensitivity locus, which also appears to govern 
oneogenesis by the  defective virus  (Table V,  R.  Risser,  unpublished  observations), 
and each antigen is expressed on spleen colony-forming cells of the bone marrow (R. 
Risser, unpublished observations). The detailed parallels of FE and Abelson antigens 
encourage  the  belief  that  these  similarities  reflect  general  principles  of  murine 
leukemogenesis. 
Summary 
Serum  from  C57BL/6  (B6)  mice  hyperimmunized with  NB-tropic  Friend  virus 
complex  (FV)  was  cytotoxic for  FV-induced  erythroleukemic spleen  cells  and  B6 
Friend-murine  leukemia  virus  (F-MuLV)  lymphoma  cells.  Cytotoxic activity  for 
erythroleukemia cells remained after repeated absorption of B6 anti-FV  antiserum 
with Friend-Moloney-Rauscher MuLV lymphoma cells but was removed by absorp- 
tion with erythroleukemia cells induced by FV or Rauscher virus. This serologic test 
system identified a  previously unrecognized cell-surface antigen of mouse leukemia, 
designated  Friend  Erythroleukemia  (FE)  antigen  to  signify  its  appearance  as  a 
determinant of virally induced erythroleukemic differentiation. FE antigen was not 
detected on 15 transplanted or primary hematopoietic neoplasms, nor was it detected 
on cells infected with ecotropic, xenotropic, or dualtropic  MuLV  isolates in  tissue 
culture. Two spleen focus-forming virus (SFFV) nonproducer cells of rats and one of 
mice express FE antigen  in  amounts comparable to primary erythroleukemia cells. 
Absorption tests with FE typing serum indicated that FE antigen was expressed on 
bone  marrow  and  spleen  but  not  thymus,  lymph  node,  or  peripheral  blood  of 
uninfected AKR, BALB/c, DBA, and SWR mice; all five tissues from B6 and C57L 
were  negative.  Quantitative  absorption  tests  indicated  that  the  expression  of FE 
antigen, though much lower than on erythroleukemic cells, was greatest on fetal liver, 
less on bone marrow, and lowest on spleen from BALB and SWR mice. Treatment of 
BALB/c or SWR fetal liver, bone marrow, spleen, thymus, or lymph node cells with 
FE typing serum did not result in significant lysis.  These observations are consistent 
with  the  interpretation  that  FE  antigen  is  expressed  by  a  minor  cell  population 
present in fetal liver, bone marrow, and spleen. Expression of FE antigen, determined 
by absorption  with  bone marrow cells,  cosegregated with  inheritance of the  Fv-2  s 
allele in the 17 inbred, 7 recombinant inbred, and 4 congenic mouse strains tested. In 
summary, the FE antigenic system identifies a cell-surface determinant that has the 
properties of a SFFV-specified antigen and hematopoietic differentiation alloantigen 
controlled by the Fv-2 locus. The similarity of FE antigen to Abelson antigen may 
provide insight into the pathogenic properties of defective transforming MuLV. REX  RISSER  1165 
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